Biogen Patent-Cliff Exposure & CMS Drug Spending Portfolio

Biogen (Cambridge, MA): 13 reconciled FDA prescription therapies, $1.29B 2024 CMS Part D & Medicaid spend, and $30,833 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterCambridge, MA
Reconciled FDA Portfolio Therapies13
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2033-01-01
2024 CMS Total Public Spend$1.29B
2024 Medicare Part D Spend$821.9M
2024 Medicaid Spend$466.6M
California HCAI SB 17 FilingsSpecialty launch notice ($30,833 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Biogen across sibling Meru public-data platforms.